Eli Lilly launches program to boost employer coverage of obesity drugs
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the…
Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its…
Eli Lilly’s lead in the obesity race gets wider after win against Novo
In the lucrative obesity drug race, there is Eli Lilly — and then there’s everybody else. A pair…
What’s next for Novo Nordisk’s obesity drug CagriSema
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…
Eli Lilly launches Zepbound obesity drug pen with one month of doses
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March…
Novo Nordisk stock falls as weight loss drug fails to beat Eli Lilly
Novo Nordisk stock fell 15% Monday after it said its next-generation weight loss drug didn’t meet its key…